Vemurafenib and cobimetinib‐induced toxic epidermal necrolysis in a patient with metastatic melanoma
| Autor: | Andy Goren, Sanja Poduje, Marija Delaš Aždajić, Ivana Prkačin, Jasmina Marić Brozić |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Proto-Oncogene Proteins B-raf medicine.medical_specialty Combination therapy medicine.medical_treatment Mucocutaneous zone Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Piperidines Antineoplastic Combined Chemotherapy Protocols medicine Humans Vemurafenib Adverse effect Melanoma Cobimetinib business.industry General Medicine Immunotherapy medicine.disease Toxic epidermal necrolysis chemistry Stevens-Johnson Syndrome 030220 oncology & carcinogenesis combined target therapy toxic epidermal necrolysis metastatic melanoma Azetidines business medicine.drug |
| Zdroj: | Dermatologic Therapy. 33 |
| ISSN: | 1529-8019 1396-0296 |
| DOI: | 10.1111/dth.13174 |
| Popis: | Combination therapy in the treatment of metastatic melanoma has been associated with more durable response rate compared to monotherapy. However, previous studies have shown that combined target therapy commonly causes a wide spectrum of adverse events. These adverse reactions are usually manageable, however, it is always necessary to compare drug efficacy with its potential adverse effects. Toxic epidermal necrolysis represents severe mucocutaneous reaction, usually triggered by medications and characterized by extensive necrosis and detachment of the epidermis. Here we present a first case of toxic epidermal necrolysis induced by combined target therapy (vemurafenib plus cobimetinib). The case was observed in a young patient with BRAF mutant melanoma who was started on first-line metastatic immunotherapy with pembrolisumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|